![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abal Group Plc | LSE:ABAL | London | Ordinary Share | GB00BFMDJC60 | ORD 0.002P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIMTK
Imaginatik PLC
16 February 2015
16 February 2015
RNS Reach
Imaginatik Plc
("Imaginatik" or the "Company")
Contracts win
Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offering a range of technology products and consultancy services, is pleased to announce that, following the trading update on 11 February 2015, it has signed two further contracts, one with a leading US based biotech company and the other with a leading Canadian media service, both of which have an initial one year term.
Under the terms of the contract with the US biotech company, Imaginatik will provide its consulting expertise and technology platforms in order to support the customer in initiating its own innovation programme. Imaginatik will help catalyse, develop and incorporate innovation capabilities across the business, enabling the customer to adjust efficiently to its evolving and dynamic marketplace.
Additionally Imaginatik will provide the technology platform and consulting support to the Canadian media service as they look to upgrade from a previous platform provider as they seek to expand and enhance their innovation strategy.
Matt Cooper, Non-Executive Chairman, commented: "I am delighted to announce that we are able to further increase our customer base and both these new contracts demonstrate the high quality offering and added value that we can deliver to our customers. We look forward to working with and expanding our reach across the biotech industry. In addition, we will support the Canadian media service in committing to Imaginatik's full platform and through this we will help catalyse and build a sustainable innovation competency within the organisation to capture new sources of value."
"These additional contract wins demonstrate that our approach and expertise continue to offer significant benefits to our customers, and enable them to develop and enhance their innovation competencies through capturing new sources of value regarding business and growth strategies."
For further information please contact:
Imaginatik plc 01329 243243 Matt Cooper - Executive Chairman Ralph Welborn - CEO Shawn Taylor - CFO finnCap Ltd 0207 220 0500 Charlotte Stranner/ Victoria Bates Newgate Threadneedle 020 7653 9850 Adam Lloyd / Edward Treadwell / Jasper Randall
About Imaginatik
Imaginatik(R) is the world's first full-service innovation provider. We have 16 years of experience building innovation into a sustainable competence at some of the world's largest and most respected companies. Through a mix of consulting and advisory, hands-on innovation projects and program management, and our award-winning enterprise software platform, we help clients develop innovation capability into a permanent competitive advantage. Imaginatik is the trusted partner of leading organisations including Blue Cross Blue Shield, CSC, Cargill, The World Bank, Mayo Clinic, The Chubb Group of Insurance Companies, HCA, Dow Chemical and Goodyear.
Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Fareham, UK. For more information visit www.imaginatik.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMGMZGKLGKZZ
1 Year Abal Chart |
1 Month Abal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions